Paul Grant Higham
Chief Executive Officer at Valo Therapeutics Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Stein | M | 60 |
Valo Therapeutics Ltd.
| 7 years |
Milla Maria Koistinaho | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 8 years |
Anthony Giovinazzo | M | 67 |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 2 years |
Heikki Matti Kalervo Hautsalo | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 8 years |
David Hinton | M | 60 |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 3 years |
Rainer Kramer | M | 60 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 12 years |
Harald F. Stock | M | 56 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 13 years |
Heike Hausfeld | F | 58 | 30 years | |
Mai-Britt Zocca | M | 56 |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 4 years |
Carsten Reinhardt | M | 57 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 15 years |
Paul Anthony Porter | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 7 years |
Matthew Vaughan | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 8 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Werner Baumann | M | 60 | 35 years | |
Niels Philipp Nikolaus Emmerich | M | 51 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 9 years |
Jürgen Frisch | M | 70 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | - |
Richard Sykes | M | 79 |
Glaxo Wellcome Plc
| 5 years |
Dattaprasad Talekar | M | 66 | - | |
William Rapeport | M | - |
Glaxo Wellcome Plc
| - |
Matthias Schuster | M | 67 | 2 years | |
Stephan Friedhelm Gerlich | M | 65 | - | |
Robert J. DiVasto | M | 68 |
Glaxo Wellcome Plc
| 10 years |
Axel Claus Heitmann | M | 64 | - | |
David Eckland | M | - |
Glaxo Wellcome Plc
| 7 years |
Helga Rübsamen-Schaeff | M | 75 | 12 years | |
Phil Thomson | M | - |
Glaxo Wellcome Plc
| 5 years |
Christoph Amberger | M | 67 | 3 years | |
Christoph Petry | M | - | 13 years | |
Thomas Fischer | M | 68 | - | |
Roger Stoll | M | 81 | 5 years | |
Hans-Peter Schaefer | M | 73 | 14 years | |
Wolfgang Schoenfeld | M | - | - | |
Christa Kreuzburg | M | 65 | 17 years | |
Peter Vanacker | M | 58 | 4 years | |
Yi-Xin Wang | M | - | 18 years | |
Alfredo Zurlo | M | - |
Glycotope GmbH
Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | - |
Richard van der Merwe | M | - | - | |
Katina Dorton | F | 66 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 2 years |
Habib Dable | M | 54 | 22 years | |
Jörg Möller | M | - | 27 years | |
Duane Tucker | M | - | 2 years | |
William Carson | M | 76 | 8 years | |
Kwok Cheung Li | M | 79 |
Glaxo Wellcome Plc
| 3 years |
Joe W. Martin | M | 71 | 12 years | |
Rainier van Roessel | M | 66 | 11 years | |
Julian Heslop | M | 70 |
Glaxo Wellcome Plc
| 2 years |
Caren Mason | F | 70 | 7 years | |
David A. Lowe | M | 77 | 5 years | |
Vikas Sinha | M | 60 | 11 years | |
Stuart J. M. Collinson | M | 64 |
Glaxo Wellcome Plc
| 4 years |
Charles W. Wolcott | M | 71 | 7 years | |
Peter Chambré | M | 68 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 8 years |
Clive Dix | M | 70 |
Glaxo Wellcome Plc
| - |
Trevor Phillips | M | 63 |
Glaxo Wellcome Plc
| 7 years |
Stephen Powell | M | 65 |
Glaxo Wellcome Plc
| 1 years |
Walter Wenninger | M | 86 | 6 years | |
J. Kenneth Charles Knowles | M | 77 |
Glaxo Wellcome Plc
| 2 years |
David Lawrence | M | 61 |
Glaxo Wellcome Plc
| 13 years |
Moise Khayrallah | M | - |
Glaxo Wellcome Plc
| 9 years |
Philip Bedford | M | - |
Glaxo Wellcome Plc
| - |
Hubertus Schmoldt | M | 79 | - | |
Jennie Younger | F | - |
Glaxo Wellcome Plc
| 12 years |
Terry Conrad | M | - | 3 years | |
Thomas F. Widmann | M | 77 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 8 years |
Harren Jhoti | M | 61 |
Glaxo Wellcome Plc
| 8 years |
Colin Foster | M | 61 | 10 years | |
Vikram Lamba | M | 58 | 8 years | |
Rolf Krebs | M | 84 | 10 years | |
Heino von Prondzynski | M | 73 | 20 years | |
Tim Tyson | M | 71 |
Glaxo Wellcome Plc
| 4 years |
John-Edward Butler-Ransohoff | M | - | 10 years |
Statistics
Country | Connections | % of total |
---|---|---|
Germany | 44 | 62.86% |
United Kingdom | 19 | 27.14% |
Finland | 7 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Grant Higham
- Personal Network